Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.11

-2.1%

Nov 13 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMarcus who wrote (5899)	1/23/2003 9:40:14 PM
From: JMarcus	Read Replies (1) of 52153

I remain very interested in EPIX, which appears to be approaching the finish line for its MRI imagent, MS-325, to replace the conventional X-ray angiogram. Here's the status of the company's four Phase III trials, as gleaned in private correspondence with a company spokesman (who confirms that this is all publicly disclosed information): <<1) the first of two trials in the aortoiliac was completed and results announced last March at the ACC conference. 2) the second of the two aortoiliac trials has completed enrollment and the blinded reads are taking place. We will announce results of that trial on March 7 at the European Congress of Radiology in Vienna, with conference call likely that morning. 3) the final two of the four Phase III trials are scheduled to complete enrollment in Q1 of '03 - and we will meet that milestone. Results for those trials will likely be announced in June/July of 03. Anticipate NDA filing in Sept/Oct '03.>> The results of the first Phase III trial were superb, the market is huge, and the company is allied with the manufacturers of MRI machines to promote use of the imagent for magnetic resonance angiography, to replace conventional X-ray angiography. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next